BCKDK抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09354(BCKDK Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09354(BCKDK Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The branched-chain α-ketoacid dehydrogenase kinase (BCKDK) is a mitochondrial kinase that regulates the activity of the branched-chain α-ketoacid dehydrogenase (BCKDH) complex, a critical enzyme in the catabolism of branched-chain amino acids (BCAAs: leucine, isoleucine, valine). By phosphorylating and inhibiting BCKDH, BCKDK suppresses the breakdown of BCAAs, thereby modulating their availability for protein synthesis and energy production. Dysregulation of BCKDK has been linked to metabolic disorders, including diabetes, obesity, and rare inborn errors like maple syrup urine disease (MSUD).

BCKDK antibodies are essential tools for studying the expression, localization, and function of BCKDK in tissues and cellular models. These antibodies enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence, helping researchers investigate BCKDK's role in metabolic homeostasis and disease. Recent studies highlight BCKDK as a potential therapeutic target; its inhibition elevates BCAA catabolism, showing promise in improving insulin sensitivity and mitigating metabolic syndrome. Additionally, BCKDK antibodies aid in exploring its interaction with other signaling pathways and its tissue-specific regulatory mechanisms.

The development of specific and high-affinity BCKDK antibodies has advanced research into BCAA-related pathologies, offering insights into nutrient-sensing networks and their impact on health. Such tools are vital for preclinical studies, including validation of BCKDK knockout models and screening of pharmacological inhibitors. Understanding BCKDK's molecular dynamics through antibody-based assays continues to drive innovations in metabolic disease research and therapeutic development.